MD Anderson Launches Phase 2 HPV Vaccine Study Evaluating Combo Therapies

Dec 10, 2018 | HPV Virus, Oncology

MD Anderson is launching a Phase 2 HPV vaccine study evaluating T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers.

Lead Research/Investigator

Michael Frumowitz, MD

0 Comments